Section 200.218 of a White House Office of Management and Budget proposal would block federal grants for any work premised on "disparate impact" — the legal idea that lets researchers measure who gets sick and who does not.
Six lines buried on page 247 of a 412-page White House budget proposal could do more to reshape American public health research than any rule issued this decade, and almost no one outside the field has read them.
The clause is Section 200.218 of the Office of Management and Budget's draft overhaul of federal grant rules, and it would bar federal funding for any research project premised on "disparate impact" theory. Disparate impact is a legal idea with a plain meaning: a policy that looks race-neutral on paper can still be treated as discriminatory if it falls harder on a protected group. For health equity researchers, that premise is the measuring stick. It is how they show that a hospital closure in a Black neighborhood, an air-quality rule that ignores bus routes, or a vaccine rollout that misses rural clinics is producing unequal harm. Without it, the field's core question, who bears which disease and why, becomes very hard to ask with federal money.
The proposal does not name the field it would defund. It does not mention health equity, race, or the National Institutes of Health. It just sets a methodological line: no federal grant dollars for work whose analytical foundation is disparate impact. Health disparities researchers interviewed by STAT News say the line, if adopted, would functionally disqualify most of what they do. Nancy Krieger, a social epidemiologist at the Harvard T.H. Chan School of Public Health, called it "perhaps the most serious threat yet" to the field's future.
The proposal itself is broader than health. It would also diminish the power of peer review in determining which grants win funding and concentrate that authority in political appointees, a structural change that has drawn thousands of public comments since the document was issued last month. But the disparate-impact bar is the piece with the most leverage, because the same premise underwrites fair-housing investigations, civil rights enforcement, employment discrimination cases, and a generation of public-health scholarship. Cut it off at the grant stage and the downstream effects compound.
The timing matters. Health disparities research rode a wave of attention at the height of the Covid-19 pandemic, when the disproportionate death toll on Black, Latino, and Native American communities made the field's questions feel newly urgent. New funding calls opened, medical journals scrambled to publish disparities work, and dozens of local governments declared racism a public health crisis. That infrastructure is what the proposal now sits on top of. Researchers say the rule would not just slow the next study. It would retroactively redraw the boundary of what the federal government will pay to know.
Since the start of the second Trump administration, health disparities researchers describe themselves as being in the crosshairs of a campaign against anything labeled "DEI". The OMB proposal reads, to its critics, as the administrative version of that campaign: a procedural mechanism that achieves the same end without the political vocabulary. Supporters frame it as a return to merit-based funding and a rollback of ideology dressed up as science. Both readings are in the public comment file. The proposal text is the cleanest place to look.
What to watch next is narrow and concrete. The comment period on the OMB proposal is open and has already drawn thousands of submissions. After that, the rule can be revised, withdrawn, or finalized. Researchers who want to argue against Section 200.218 specifically, rather than the politics around it, are filing technical comments that the legal premise of disparate impact is not an ideological commitment but a measurement tool used by courts, regulators, and the Centers for Disease Control and Prevention alike. If those comments land, the clause can be narrowed. If they do not, the next round of NIH funding decisions will be the first place the rule does its work, and the first place the field's contraction will become visible.